SPY319.40+8.04 2.58%
DIA271.51+8.18 3.11%
IXIC9,814.08+198.27 2.06%

RBC Capital Initiates Coverage On Arrowhead Pharmaceuticals with Outperform Rating, Announces Price Target of $62

RBC Capital initiates coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Outperform rating and announces Price Target of $62.

Benzinga · 05/13/2020 08:59

RBC Capital initiates coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Outperform rating and announces Price Target of $62.